Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ian Schofield

Executive Editor

Edinburgh, UK
Ian specialises in pharmaceutical regulatory affairs, mainly in the EU and the UK but also in Australia, New Zealand, Canada and certain African markets. His key areas of focus are clinical trials, market access, intellectual property issues, global regulatory alignment and pandemic preparedness. A modern languages graduate, he worked in the European travel industry before joining Scrip in 1985 as a reporter covering the French and Italian markets. He subsequently held posts including Deputy Editor of Scrip and Principal Analyst at Informa, before taking up his current position at the Pink Sheet. As well as writing news, features and analysis, Ian is part of the Ask the Analyst team that produces on-demand tailored reports for subscribers. His non-work interests include cycling, travel, paddleboarding and playing traditional Scottish music.

Latest From Ian Schofield

UK Regulator Says April Fee Rise Will Support 'Innovative & Efficient' Service

The Medicines and Healthcare products Regulatory Agency says that the fee increases to be introduced on 1 April, along with 18 new fees, are necessary for its long-term financial sustainability and its ability to provide a “responsive, innovative and efficient regulatory service.”

Europe United Kingdom

Regulatory Flexibilities Help Ease EU Amoxicillin Shortages

The European Medicines Agency says that the current shortage of antibiotics containing amoxicillin is not a “major event” and that efforts by EU and national regulators are helping to mitigate the situation.

Europe Infectious Diseases

UK Prepares For New International Regulatory Reliance Framework

From next year, more agencies will be involved in the UK’s regulatory reliance procedure for new drug approvals, which was first introduced in 2021 to allay fears of post-Brexit delays to UK applications. The pharmaceutical industry said it looked forward to working with the regulator on the new framework.

Europe United Kingdom

Industry Warns Of New Post-Brexit ‘Cliff Edge’ For Medicines Supply To Northern Ireland

The burden of having to produce separate product packs for Great Britain and Northern Ireland is among a number of concerns raised by industry executives at a recent hearing in the House of Lords.

United Kingdom Europe

Industry Warns Of New Post-Brexit ‘Cliff Edge’ For Medicines Supply To Northern Ireland

The burden of having to produce separate product packs for Great Britain and Northern Ireland is among a number of concerns raised by industry executives at a recent hearing in the House of Lords.

Europe United Kingdom

Australian Committee Wants HTA Review To Begin Early In 2023

At its next meeting, the Australian committee responsible for reviewing the country's health technology assessment system will discuss feedback from stakeholders, including the pharmaceutical industry, on the draft terms of reference for the review.

Australia Health Technology Assessment
See All
UsernamePublicRestriction

Register